Concepedia

Publication | Open Access

Cost-effectiveness of Bezlotoxumab Compared With Placebo for the Prevention of Recurrent Clostridium difficile Infection

DOIFull Paper Access

66

Citations

23

References

2017

Year

Vimalanand S. Prabhu, Erik R. Dubberke, Elamin H. Elbasha, Nicole Cossrow, Yiling Jiang, Stephen Marcella
Clinical Infectious Diseases

Abstract

Model-based results demonstrated that bezlotoxumab was cost-effective in the prevention of recurrent CDI compared with placebo, among patients receiving SoC antibiotics for treatment of CDI.

References

YearCitations

Page 1